Clinical observation of Diyu Shengbai tablets in prevention and treatment of leukopenia caused by linezolid in patients with multidrug-resistant tuberculosis
JIANG Huailong
HU Weihua
LI Hongyu
ZHANG Xiaolei
LI Qijian
HAN Shan
JIN Long
Abstract：Objective To observe the clinical effects of Diyu Shengbai tablets in the prevention and treatment of leu-kopenia caused by linezolid in patients with multidrug-resistant tuberculosis(MDR-TB).Methods Sixty-six patients with MDR-TB to be treated with linezolid were selected and randomly divided into the treatment group of 31 cases and con-trol group of 35 cases.Patients in both groups were treated with an anti-tuberculosis regimen containing linezolid;in the treatment group,patients were orally administered Diyu Shengbai tablets,0.4 g each time,3 times each day for 3 months.For those who developed leukopenia within 2 months of linezolid treatment in the control group,they were instructed to orally take Diyu Shengbai tablets,0.4 g each time,3 times each day for 1 month.The occurrence of leukopenia and neu-tropenia at 1,2 and 3 months of treatment was recorded in both groups.We compared the white blood cell counts and neu-trophil counts of leukopenic patients who developed leukopenia in the control group within 2 months of linezolid treatment with Diyu Shengbai tablets before treatment and after 1 month of treatment,and then calculated the overall effective rate af-ter evaluating their therapeutic efficacy.Liver and kidney functions were monitored during 3 months of anti-tuberculosis treatment in the treatment group and the control group without Diyu Shengbai tablets,and abnormalities of liver and kidney functions were recorded.Results No leukopenia occurred in the treatment group at 1,2,and 3 months of treatment,and 3,4,and 2 cases of leukopenia occurred in the control group at 1,2,and 3 months of treatment,respectively,with an overall incidence of leukopenia of 25.7%(9/35);the overall incidence of leukopenia at 3 months of treatment was low-er in the treatment group than in the control group(P<0.05).No neutropenia occurred in the treatment group at 1,2,and 3 months of treatment,and 2,4,and 2 cases of neutropenia occurred in the control group at 1,2,and 3 months of treat-ment,respectively,with an overall incidence of neutropenia of 22.9%;the overall incidence of neutropenia at 3 months of treatment was lower in the treatment group than in the control group(P<0.05).The leukocyte counts of patients with leu-kopenia in the control group before and after treatment were(2.90±0.93)×109 and(4.47±1.46)×109/L,respectively,and the neutrophil counts were(1.45±0.54)×109 and(2.64±1.27)×109/L,respectively;compared with those before treatment,the leukocyte counts and neutrophil counts of the control group increased after the treatment(both P<0.05).Within 2 months of linezolid treatment,among the 7 cases of leukopenia in the control group treated with Diyu Shengbai tablets,5 showed marked effect,1 showed effective response,and 1 was ineffective,resulting in a total effective rate of 85.71%.There was no statistically significant difference in the incidence of liver function abnormalities during treatment between the two groups(P>0.05),and the incidence of kidney function abnormalities during treatment in the treatment group was lower than that in the control group who did not use Diyu Shengbai tablets(P<0.05).Conclusion Diyu Shengbai tablets are effective and safe for the prevention and treatment of leukopenia caused by linezolid in MDR-TB pa-tients.
Keywords：Diyu Shengbai tabletlinezolidmultidrug-resistant tuberculosismyelosuppressionleukopenianeutropenia
Publication Date：2025-03-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 12-16 )